<DOC>
	<DOCNO>NCT02437916</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics , anti-tumor activity , identify tolerable dose AMG 228 subject advance solid tumor .</brief_summary>
	<brief_title>Safety Study AMG 228 Treat Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Subject must pathologically document , definitively diagnose , advance solid tumor Adequate hematological , renal , hepatic , coagulation laboratory assessment Active autoimmune disease , history autoimmune disease Treatment immune modulators include Use warfarin , factor Xa inhibitor , direct thrombin inhibitor Antitumor therapy ( chemotherapy , antibody therapy , molecular target therapy , investigational agent ) within 28 day Major surgery within 28 day study day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Non-small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Head Neck</keyword>
	<keyword>Transitional Cell Carinoma ( TCC )</keyword>
	<keyword>Bladder</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Colorectal Cancer ( CRC )</keyword>
</DOC>